Assembly Biosciences (ASMB) said Wednesday a phase 1b trial of its drug candidate ABI-4334 showed 'strong' antiviral activity in chronic hepatitis B patients.
Two groups of 10 patients with different doses met the safety profile supporting once-daily oral dosing for a 28-day treatment, the company said, adding there were no serious adverse events or adverse events that led to the study drug discontinuation.
Assembly Biosciences also said Gilead Sciences (GILD), under its collaboration with Assembly, may opt for an exclusive license for further development based on the trial's findings.
Shares of the company were up over 1.2% in recent Wednesday premarket activity. Gilead's shares were down 0.1%.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。